AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing facility at 10 Aeropark Boulevard in Hamilton, Ontario. The milestone marks a defining moment in AtomVie's evolution that transforms clinical success into life-changing precision therapies for patients worldwide.
, AtomVie is a spinout of the Centre for Probe Development and Commercialization (CPDC), a McMaster University-based Centre of Excellence established to advance Canada's leadership in radiopharmaceutical innovation and manufacturing. Today, AtomVie employs a growing team of highly skilled professionals, with the organization targeting more than 200 employees by the end of 2026 as the new site continues to scale toward full operations.
"This Grand Opening represents the next chapter of AtomVie's journey and a proud milestone for Canadian innovation in nuclear medicine," said Bruno Paquin, Chief Executive Officer of AtomVie. "Our new purpose-built facility amplifies a proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialization of our partners' pipelines. Above all, it advances our purpose of transforming patients' lives by delivering high-quality radiopharmaceuticals to those who need them, all around the world."
"AtomVie's new facility inauguration reflects the discipline and dedication of the AtomVie team and the confidence of the partners who have supported our growth," said Kevin McNeill, Chairman of AtomVie's Board of Directors. "This facility continues AtomVie's status as a leading radiopharmaceutical CDMO, now built at commercial scale to serve partners with the reliability the field requires."